相关实验视频

Updated: May 2, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

在三阴性乳腺癌中对辅助剂capecitabine剂量模式的回顾性评估

Kun Lin¹, Elena Michaels², Eric Polley³

¹Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

|October 14, 2024

概括

辅助剂capecitabine对三阴性乳腺癌 (TNBC) 有效,但耐受性较差. 这项研究在多样化的美国队列中发现了较低的相对剂量强度 (RDI),这表明可能需要调整剂量以提高TNBC患者的耐受性.

科学领域:

在瘤学瘤学.
临床药理学临床药理学
乳腺癌研究研究乳腺癌研究

背景情况:

辅助性capecitabine提高了高风险三阴性乳腺癌 (TNBC) 的存活率.
美国人通常不能很好地容忍标准剂量的capecitabine.
需要分析不同队列中的剂量模式,以指导耐受性和剂量.

研究的目的:

分析种族多样化的TNBC队列中的capecitabine剂量模式.
描述耐受性,并为TNBC中辅助剂capecitabine的未来剂量指南提供信息.

主要方法:

对接受辅助性capecitabine的TNBC患者进行单中心回顾性研究.
主要终点:八个周期的相对剂量强度 (RDI).
根据年龄,种族,BMI和初始剂量进行分组分析;二次终点:副作用和存活率.

主要成果:

平均RDI为60.2%,明显低于CREATE-X试验 (0.787,p < 0.001).
根据年龄,种族,BMI或初始剂量,RDI没有显著差异.
常见的不良事件:手脚综合征 (73%),腹 (27%),疲劳 (22%).

结论:

很大一部分患者能耐受低于推剂量的capecitabine.
在这个队列中,RDI不受人口因素或初始剂量的显著影响.
需要进一步的研究来优化capecitabine剂量,以提高TNBC的耐受性.

关键词:

辅助剂卡佩西塔 (capecitabine) 是一种药物.相对剂量强度的相对剂量强度.安全性和耐受性.三重阴性乳腺癌是什么

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...